BioTech
To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare’s worst option
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight loss drugs with price tags that could effectively bankrupt the
Melissa Barber, Joseph S. Ross, and Reshma Ramachandran
July 23, 2024